According to previous studies, blockade of the CXCL12/CXCR4 axis by the specific antagonist AMD3100 attenuates experimental colitis in a murine model by inhibiting chronic inflammation and enhancing epithelial barrier integrity [41, 42]. Here, CXCR4 is linked to colitis.